DRKS00024484已完成2 期
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression (EPIsoDE) - EPIsoDE
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 25 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1) 25 to 65 years of age
- •2) Diagnosis of major depressive disorder (single and recurrent episodes) of moderate to severe degree (HAM-D score = 17) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) without psychotic features. Included ICD-10 diagnoses are ICD-10: F32.1, F32.2, F33.1, F33.2.
- •a. If single episode, duration must be = 3 months.
- •3) Patients must meet criteria for treatment-resistance, defined as
- •a. no adequate improvement despite two adequate courses of antidepressant treatment (6 weeks each, minimum) with drugs of different pharmacological classes in the current depressive episode. Augmentation with an add-on treatment counts as a second treatment.
- •4) Patients have discontinued any monoaminergic psychiatric medication (i.e. SRIs, antipsychotic medication) for at least 2 weeks before the first dosing session.
- •Patients who are still on any monoaminergic psychiatric medication at screening must agree to down-titrate over an individualized down-titration schedule (minimum 2 weeks; if they have been taken Fluoxetine the down-titration phase should be minimum 5 weeks) in close supervision by their out-patient psychiatrist and the study team. The treating psychiatrist must agree to supervise and monitor the down-titration and to collaborate with the study team by signing a treatment agreement form.
- •If the treating psychiatrist refuses to monitor the down-titration, the patient has to agree to down-titrate under supervision of clinicians in the outpatient clinics of the two study sites or trial physicians and to come in for weekly monitoring visits.
- •5) The subjects are abstinent from alcohol (breathalyzer blood alcohol concentration (BAC) level 0.00) and a negative urine drug screen at days of dosing
- •6) The subject must be medically stable based on clinical laboratory tests, medical history, vital signs, and 12-lead ECG performed at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, retesting of an abnormal lab value(s) that may lead to exclusion will be allowed once during the screening phase. In 12-lead ECG, QTcF should be = 450 ms for males or = 470 ms for females and PR-interval < 220 ms at screening. A retest of an abnormal ECG value will be allowed once in the screening phase. Blood pressure will be the average of 2 measurements. The subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject's source documents and initialed by the investigator.
- •7) The subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
- •8) The subject must sign an informed consent form indicating that he/she understands the purpose of and procedures required for the study including peripheral biomarker monitoring (i.e. blood) and is willing to participate in the study.
排除标准
- •1) Currently comorbid or previously diagnosed DSM-5 diagnosis of a
- •major depressive episode with psychotic features/major depressive disorder with psychotic features (ICD-10: F32.3)
- •schizophrenia spectrum and other psychotic disorders, including schizotypal (personality) disorders, delusional disorder, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, substance/medication-induced psychotic disorder and psychotic disorder due to another medical condition (ICD-10: F20 - F29)
- •bipolar and related disorders (ICD-10: F30/F31)
- •cluster A personality disorders (paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder) and/or borderline personality disorder (Patients will be carefully screened for presence of those personality disorders by using the SCID-5-PD)
- •Post-traumatic stress disorder (PTSD; ICD-10: F43.1)
- •2) A family history (first-degree relative) of psychosis and/or bipolar disorder
- •The subject has a current or recent history of clinically significant suicidal ideation within the past 6 months, corresponding to a score of 4 (active suicidal ideation with some intent to act, without specific plan) or 5 (active suicidal ideation with specific plan and intent) for ideation on the C-SSRS, or a history of suicidal behavior within the past 1 year, as validated by the C-SSRS at screening.
- •3) Subjects with a prior suicide attempt of any sort, or prior serious suicidal ideation/plan > 6 months ago, should be carefully screened for current suicidal ideation and only included at the discretion of the investigator.
- •4) Current comorbid psychiatric diagnosis except their major diagnosis (inclusion criterion 3) in form of
- •a. Diagnoses mentioned under exclusion criterion 1) b. Substance use disorder (except tobacco-related disorders/caffeine-related disorders) i. Alcohol consumption must be limited to = 40 gram for men and = 20 gram for women per day, e.g. = two/one large beer (0.5 l) for men/women.
- •5) Use of classical psychedelics (i.e. LSD, psilocybin, mescaline, dimethyltryptamine) in the past year and or more than five life-time uses of classical psychedelics.
- •6) Failure to establish sufficient rapport with the two therapists as judged by them after the first two preparation sessions
- •7) Lithium intake
- •8) The patient has any disorder for which the treatment takes priority over treatment of depression or is likely to interfere with the study treatment or impair treatment compliance. This includes current signs/symptoms of liver or renal insufficiency, hypothyroidism or hyperthyroidism (subjects who are on stable treatment with thyroid supplementation and show an euthyroid metabolism with normal thyroid-stimulating hormone [TSH] may participate), significant cardiac disease (including current or past history of atrial fibrillation/flutter), vascular, pulmonary, endocrine, neurologic (including epilepsy), hematologic, inflammatory (e.g., rheumatoid arthritis, inflammatory bowel disease, Crohn's disease) or metabolic diseases as long as these diseases are not medically controlled or might significantly interfere with participation in the study. Diabetes mellitus (DM) may be allowed when blood glucose is stably controlled (HbA1c less than 7.5% or 58 mmol/mol).
- •a. To rule out the presence of any serious neurological condition that might be underlying the depression (e.g. Parkinson's Disease, dementia), patients must provide a recent (i.e. not older than 5 years) brai
研究者
相似试验
招募中
Unknown
Psilocybin administration for treatment-resistant depressiodepressionD061218Treatment-resistant depressionJPRN-jRCTs031230351chida Hiroyuki12
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873EUCTR2017-003288-36-CZCOMPASS Pathfinder, Limited216
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873EUCTR2017-003288-36-IECOMPASS Pathfinder, Limited216
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioEUCTR2017-003288-36-PTCOMPASS Pathfinder Limited216
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873EUCTR2017-003288-36-DECOMPASS Pathfinder, Limited398